iTind for Benign Prostatic Hyperplasia Gets FDA Green Light

Medi-Tate, based in Israel, has won FDA de novo authorization for its iTind system to treat benign prostatic hyperplasia.The minimally invasive system is…

Sourced through Scoop.it from: www.medgadget.com